Effects of Diet and Osteopathy on Quality of Life and Inflammation in Breast Cancer Patients Under Hormonal Therapy (SECCO)

A Randomised Effectiveness-implementation Trial for Evaluating Dietary and Manual Treatment With Osteopathic Techniques on Quality of Life and on Modulation of the Inflammatory State of Patients Diagnosed With Breast Cancer Undergoing Antiestrogenic Hormonal Treatment.

Breast cancer patients under hormonal therapy may experience significant adverse events related to this treatment and as a result, failure to adhere to adjuvant therapies or discontinuation of treatment has been reported to be high.

Promoting weight control and the adoption of healthy lifestyle habits in breast cancer survivors has an impact on hormonal status, quality of life and physical functioning, contributing to reduce cancer recurrence risk, cancer-related and chronic-condition-related mortality.

Manipulation procedures, such as manual treatment with osteopathic techniques, have positive effects on osteoarticular pain, peripheral neuropathies, anxious-depressive disorders, asthenia and sleep disorders, also improving immune and neuroendocrine responses.

The aim of this study is to evaluate the effects of dietary intervention and manual treatment with osteopathic techniques in women diagnosed with breast cancer under antiestrogenic hormonal treatment through the assessment of:

• modifications of quality of life (QoL)
• frequency and severity of symptoms related to antiestrogenic hormonal treatment
• body weight
• body composition
• food habits
• metabolic and inflammatory state
• physical performance
• patient's satisfaction to multidisciplinary treatment.

This study focuses on patient's centricity evaluating the effects that long lasting adjuvant therapies have on breast cancer survivors. Improving personalized patient's treatment through collaborative interactions between clinicians, osteopaths and nutrition specialists might result in implementation strategies to determine novel evidence-based treatments for ameliorating patient's adherence to oncological therapies, impacting prognosis and survival.

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer
• Intervention / Treatment: Other: manual treatment with osteopathic techniques and nutritional treatment; Other: manual treatment with osteopathic techniques; Other: nutritional treatment

Detailed Description

Breast cancer patients under hormonal therapy may experience significant adverse events related to this treatment. Premenopausal women may encounter the classic symptoms of menopausal syndrome: hair thinning or loss; hot flashes, sweating, fatigue, insomnia, joint pain, vaginal dryness, decreased libido, anxious-depressive disorders, cognitive dysfunction; dry eyes; weight gain. Postmenopausal women may instead experience joint stiffness and joint pain, depressive and anxious symptoms, fatigue and irritability.

Since most of these adverse events do not resolve spontaneously a few weeks/months after starting treatment, they often negatively impact patient's quality of life.

As a result of treatment-related adverse events, failure to adhere to adjuvant therapies or discontinuation of treatment has been reported to be high and this may negatively impact patient's prognosis and survival.

Patients with breast cancer frequently experience weight gain during and after adjuvant hormonal treatment. Indeed, menopause, musculoskeletal pain and the consequent physical activity reduction, work together to reduce the basal energy metabolism. On the other side, the psychological distress and the eventual use of food for emotional reward, do promote weight gain. Notably, breast cancer patients who are overweight or obese show an increased risk of overall mortality, cancer-specific mortality, breast cancer relapse or second primary contralateral breast cancer. The explanation lies in the fact that the increase in fat mass is directly correlated to an increased production of estrogens, insulin, leptin and proinflammatory cytokines which, all together, exhibit a mitogenic activity on mammary cells. Proinflammatory cytokines and insulin deregulation on their turn, favor with time the onset of other chronic diseases such as diabetes, dyslipidemia, metabolic syndrome in general, thus increasing the risk of overall mortality. Conversely, weight loss can improve hormonal status, quality of life and physical functioning and contribute to reduce cancer recurrence risk, cancer-related and chronic-condition-related mortality. Therefore, it is important to promote weight control and the adoption of healthy lifestyle habits in breast cancer survivors.

Manipulation procedures, such as manual treatment with osteopathic techniques, involve the mechanical displacement of fluids and the removal of toxic substances with neurovascular and neuromuscular effects, thus producing positive alterations at the metabolic, biochemical and circulatory level. Several studies conducted on patients with breast cancer have supported the positive effect of manual therapy (acupuncture, shiatsu treatments, massages) on the control of various problems such as osteoarticular pain, peripheral neuropathies, anxious-depressive disorders, asthenia and sleep disorders, also improving immune and neuroendocrine responses.

Nevertheless, there are no studies on the effect of manual treatment with osteopathic techniques on the control of symptoms related to the side effects induced by anti-tumor therapies.

The aim of this study is to evaluate the effects of dietary intervention and manual treatment with osteopathic techniques in women diagnosed with breast cancer under antiestrogenic hormonal treatment through the assessment of:

• modifications of quality of life (QoL)
• frequency and severity of symptoms related to antiestrogenic hormonal treatment
• body weight
• body composition
• food habits
• metabolic and inflammatory state
• physical performance
• patient's satisfaction to multidisciplinary treatment.

This study focuses on patient's centricity evaluating the effects that long lasting adjuvant therapies have on breast cancer survivors. Improving personalized patient's treatment through collaborative interactions between clinicians, osteopaths and nutrition specialists might result in implementation strategies to determine novel evidence-based treatments for ameliorating patient's adherence to oncological therapies, impacting prognosis and survival.

• Study Type: Interventional
• Enrollment (Estimated): 600
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Cristina Ferraris, MD; Phone Number: +39 02 2390 2659; Email: cristina.ferraris@istitutotumori.mi.it
• Study Contact Backup: Name: Chiara Listorti, MD; Phone Number: +39 02 2390 2659; Email: chiara.listorti@istitutotumori.mi.it

Study Locations

• Italy
  • Milan, Italy, 20133
    • Recruiting
    • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Contact: Chiara Listorti, MD; Phone Number: +39 02 2390 2659; Email: chiara.listorti@istitutotumori.mi.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age >18 years
• Voluntary written informed consent
• Histologically confirmed estrogen receptor-positive invasive breast cancer or in situ breast cancer after breast surgery
• Absence of locoregional relapse or distant metastasis
• Premenopausal or postmenopausal status
• Hormonal therapy with tamoxifen and/or LHRH analogues or aromatase inhibitors
• Patients with or without neoadjuvant or adjuvant chemotherapy
• Patients with a BMI > 18.5 kg/m^2
• Absence of language barrier

Exclusion Criteria:

• Previous hormonal therapy
• Use of medical treatments that contrast adjuvant hormonal therapy adverse effects (e.g. menopausal symptoms and arthralgia).
• Underweight patients (BMI <18.5 kg/m^2)
• Patients diagnosed with eating disorders (e.g. anorexia nervosa, bulimia, binge eating, orthorexia)
• Psychiatric disorders or cognitive impairments
• Previous malignancies other than in situ cervical carcinoma or non-melanoma skin cancer
• Non-epithelial breast cancer at histological examination
• In situ lobular breast cancer
• Participation in other randomized clinical trials that could interfere with current study
• Patients living distant from trial center and unable to attend for check-ups and meetings.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Single

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A1: manual treatment with osteopathic techniques and nutritional treatment in premenopausal patients; Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet).	Other: manual treatment with osteopathic techniques and nutritional treatment; manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
Experimental: A2: manual treatment with osteopathic techniques in premenopausal patients; Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques).	Other: manual treatment with osteopathic techniques; manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
Experimental: A3: nutritional treatment in premenopausal patients; Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with nutritional treatment (personalized Mediterranean Diet).	Other: nutritional treatment; nutritional treatment (personalized Mediterranean Diet)
No Intervention: A4: control group in premenopausal patients; Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues receive general counselling on healthy dietary habits and lifestyle in accordance to the World Cancer Research Fund (WCRF) guidelines.
Experimental: B1: osteopathic techniques and nutritional treatment in postmenopausal patients; Postmenopausal breast cancer patients under aromatase inhibitors are treated with manual treatment (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet).	Other: manual treatment with osteopathic techniques and nutritional treatment; manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
Experimental: B2: manual treatment with osteopathic techniques in postmenopausal patients; Postmenopausal breast cancer patients under aromatase inhibitors are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques).	Other: manual treatment with osteopathic techniques; manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
Experimental: B3: nutritional treatment in postmenopausal patients; Postmenopausal breast cancer patients under aromatase inhibitors are treated with nutritional treatment (personalized Mediterranean Diet).	Other: nutritional treatment; nutritional treatment (personalized Mediterranean Diet)
No Intervention: B4: control group in postmenopausal patients; Postmenopausal breast cancer patients under aromatase inhibitors receive general counselling on healthy dietary habits and lifestyle in accordance to the World Cancer Research Fund (WCRF) guidelines.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the effect of dietary intervention and manual treatment with osteopathic techniques on quality of life (QoL) of women diagnosed with breast cancer under hormonal treatment	Quality of life will be assessed using the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) questionnaire comparing the before-and-after treatment difference in FACT-ES QoL scale (range 0-200; the higher the FACT-ES score, the better the quality of life, QoL) evaluated at baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3). The difference between pre treatment (baseline, T0) score and 24-weeks (six months, T2) score of the FACT ES QoL scale will be analyzed by ANOVA, and the interaction between the dietetic treatment and manual treatment with osteopathic techniques will be tested at 5% significance level. In a secondary ANOVA analysis, the baseline-to-52-weeks (T3) follow-up difference of the FACT ES QoL scale scores will additionally be analyzed. These analyses will be conducted separately in Groups A and B.	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body weight	Body weight will be evaluated using body mass index (BMI), measuring weight in kilograms divided by the square of height in meters.	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Body composition	Body composition will be evaluated combining two anthropometric measures: the waist circumference (cm) and calf circumference (cm).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Food habits	Food habits will be assessed through a food frequency questionnaire.	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Hemoglobin	Hemoglobin will be assessed collecting blood exams measuring hemoglobin levels (g/dL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Red blood cells	Red blood cells will be assessed collecting blood exams measuring red blood cells count (cells/mcL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Platelets	Platelets will be assessed collecting blood exams measuring platelets count (cells/mcL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
White blood cells	White blood cells will be assessed collecting blood exams measuring white blood cells count (cells/mcL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Lymphocytes	Lymphocytes will be assessed collecting blood exams measuring lymphocytes count (cells/mcL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Monocytes	Monocytes will be assessed collecting blood exams measuring monocytes count (cells/mcL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Neutrophils	Neutrophils will be assessed collecting blood exams measuring neutrophils count (cells/mcL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Inflammatory state: erythrocyte sedimentation rate	inflammatory state will be assessed collecting blood exams measuring erythrocyte sedimentation rate (ESR) (mm/h)	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Vitamin D	Vitamin D will be assessed collecting blood exams measuring Vitamin D levels (ng,mL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Metabolic state: plasma glycemia	Metabolic state will be assessed collecting blood exams measuring plasma glycemia (mg/dl)	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Metabolic state: serum insulin concentration	Metabolic state will be assessed collecting blood exams measuring serum insulin concentration (µU/ml).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Metabolic state: total cholesterol	Metabolic state will be assessed collecting blood exams measuring total cholesterol (mg/dL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Metabolic state: low-density lipoprotein (LDL) cholesterol	Metabolic state will be assessed collecting blood exams measuring low-density lipoprotein (LDL) cholesterol (mg/dL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Metabolic state: high-density lipoprotein (HDL) cholesterol	Metabolic state will be assessed collecting blood exams measuring high-density lipoprotein (HDL) cholesterol (mg/dL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Metabolic state: triglycerides	Metabolic state will be assessed collecting blood exams measuring triglycerides (mg/dL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Inflammatory state: c-reactive protein (CRP)	inflammatory state will be assessed collecting blood exams measuring c-reactive protein (CRP) (mg/L).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Sex hormone binding globulin (SHBG)	Sex hormone binding globulin (SHBG) will be assessed collecting blood exams measuring sex hormone binding globulin levels (SHBG) (nmol/L).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Inflammatory state: Interleukin-6 (IL-6)	inflammatory state will be assessed collecting blood exams measuring Interleukin-6 (IL-6) levels (pg/mL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Inflammatory state: Tumour necrosis factor-α (TNF-α)	inflammatory state will be assessed collecting blood exams measuring Tumour necrosis factor-α (TNF-α) levels (pg/ml).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Testosterone	Testosterone levels will be assessed collecting blood exams measuring testosterone levels (ng/dL).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Modifications of blood lipid profile	modifications of blood lipid profile will be assessed collecting blood exams measuring plasma lipids by UPLC-MS.	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Treatment-related adverse events of hormonal treatment in premenopausal and postmenopausal patients	Symptoms related to hormonal treatment will be evaluated using Menopause Rating Scale (MRS) (range 0-44; higher scores indicating worse symptoms) in Group A and EORTC Quality of Life Questionnaire - Breast Cancer Module (EORTC-QLQ-C30/BR23) (range 0-100; higher scores corresponding to worse symptoms) in Group B, respectively.	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Physical performance	Physical performance will be assessed using International Physical Activity Questionnaires (IPAQ) measuring physical activity levels (higher scores indicating higher physical activity).	baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)
Patient's satisfaction to multidisciplinary treatment	Patient's satisfaction to multidisciplinary treatment will be assessed with Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General questionnaire (FACIT-TS-G) (range 0-25; the higher the score, the better the satisfaction).	12 weeks (T1), after 24 weeks (T2) and after 52 weeks (T3)

Collaborators and Investigators

• Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
• Investigators: Principal Investigator: Cristina Ferraris, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Publications and helpful links

General Publications

• Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB.
• Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, Pahor M, Satterfield S, Brach JS, Studenski SA, Harris TB. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA. 2006 May 3;295(17):2018-26. doi: 10.1001/jama.295.17.2018.
• Ingber DE, Wang N, Stamenovic D. Tensegrity, cellular biophysics, and the mechanics of living systems. Rep Prog Phys. 2014 Apr;77(4):046603. doi: 10.1088/0034-4885/77/4/046603.
• Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012 Jul;134(2):459-78. doi: 10.1007/s10549-012-2114-5. Epub 2012 Jun 12.
• Morey MC, Snyder DC, Sloane R, Cohen HJ, Peterson B, Hartman TJ, Miller P, Mitchell DC, Demark-Wahnefried W. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA. 2009 May 13;301(18):1883-91. doi: 10.1001/jama.2009.643.
• Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010 Oct;123(3):627-35. doi: 10.1007/s10549-010-0990-0. Epub 2010 Jun 23.
• Reeves MM, Terranova CO, Eakin EG, Demark-Wahnefried W. Weight loss intervention trials in women with breast cancer: a systematic review. Obes Rev. 2014 Sep;15(9):749-68. doi: 10.1111/obr.12190. Epub 2014 May 29.
• Kangas M, Henry JL, Bryant RA. Posttraumatic stress disorder following cancer. A conceptual and empirical review. Clin Psychol Rev. 2002 May;22(4):499-524. doi: 10.1016/s0272-7358(01)00118-0.
• Kim Y, Park I, Kang M. Convergent validity of the international physical activity questionnaire (IPAQ): meta-analysis. Public Health Nutr. 2013 Mar;16(3):440-52. doi: 10.1017/S1368980012002996. Epub 2012 Jul 2.
• Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012 Mar 20;30(9):936-42. doi: 10.1200/JCO.2011.38.0261. Epub 2012 Feb 13.
• Piccoli A, Rossi B, Pillon L, Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. Kidney Int. 1994 Aug;46(2):534-9. doi: 10.1038/ki.1994.305. No abstract available.
• Williams NH, Hendry M, Lewis R, Russell I, Westmoreland A, Wilkinson C. Psychological response in spinal manipulation (PRISM): a systematic review of psychological outcomes in randomised controlled trials. Complement Ther Med. 2007 Dec;15(4):271-83. doi: 10.1016/j.ctim.2007.01.008. Epub 2007 Mar 8.
• Wolfenden L, Foy R, Presseau J, Grimshaw JM, Ivers NM, Powell BJ, Taljaard M, Wiggers J, Sutherland R, Nathan N, Williams CM, Kingsland M, Milat A, Hodder RK, Yoong SL. Designing and undertaking randomised implementation trials: guide for researchers. BMJ. 2021 Jan 18;372:m3721. doi: 10.1136/bmj.m3721.
• Patterson RE, Cadmus LA, Emond JA, Pierce JP. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas. 2010 May;66(1):5-15. doi: 10.1016/j.maturitas.2010.01.004. Epub 2010 Jan 25.
• Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, Boyce LM, Tripathy D. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017 May 6;67(3):194-232. doi: 10.3322/caac.21397. Epub 2017 Apr 24.
• Bach-Faig A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Dernini S, Medina FX, Battino M, Belahsen R, Miranda G, Serra-Majem L; Mediterranean Diet Foundation Expert Group. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 2011 Dec;14(12A):2274-84. doi: 10.1017/S1368980011002515.
• Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402-24. doi: 10.1159/000442721. Epub 2015 Dec 5. Erratum In: Obes Facts. 2016;9(1):64.
• Sauter ER. Breast Cancer Prevention: Current Approaches and Future Directions. Eur J Breast Health. 2018 Apr 1;14(2):64-71. doi: 10.5152/ejbh.2018.3978. eCollection 2018 Apr.
• Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3.
• Martino G, Catalano A, Agostino RM, Bellone F, Morabito N, Lasco CG, Vicario CM, Schwarz P, Feldt-Rasmussen U. Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer. PLoS One. 2020 Mar 26;15(3):e0230681. doi: 10.1371/journal.pone.0230681. eCollection 2020.
• Glaus A, Boehme Ch, Thurlimann B, Ruhstaller T, Hsu Schmitz SF, Morant R, Senn HJ, von Moos R. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol. 2006 May;17(5):801-6. doi: 10.1093/annonc/mdl030. Epub 2006 Feb 28.
• Mantas, D., Kostakis, J.D. & Markopoulos, C. Aromatase inhibitors: A comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients. Hellenic J Surg 88, 245-251 (2016). https://doi.org/10.1007/s13126-016-0326-6
• Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU; ATAC Trialists' Group. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008 Sep;9(9):866-72. doi: 10.1016/S1470-2045(08)70182-7. Epub 2008 Aug 12.
• Vance V, Mourtzakis M, Hanning R. Relationships Between Weight Change and Physical and Psychological Distress in Early-Stage Breast Cancer Survivors. Cancer Nurs. 2019 May/Jun;42(3):E43-E50. doi: 10.1097/NCC.0000000000000612.
• Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.
• Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 Apr;126(2):529-37. doi: 10.1007/s10549-010-1132-4. Epub 2010 Aug 28.
• Hernandez-Reif M, Ironson G, Field T, Hurley J, Katz G, Diego M, Weiss S, Fletcher MA, Schanberg S, Kuhn C, Burman I. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. J Psychosom Res. 2004 Jul;57(1):45-52. doi: 10.1016/S0022-3999(03)00500-2.
• Lissoni P, Messina G, Lissoni A, Franco R. The psychoneuroendocrine-immunotherapy of cancer: Historical evolution and clinical results. J Res Med Sci. 2017 Apr 26;22:45. doi: 10.4103/jrms.JRMS_255_16. eCollection 2017.
• Borreani C, Alfieri S, Infante G, Miceli R, Mariani P, Bosisio M, Vernieri C, Bianchi GV, Capri G. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. Oncology. 2021;99(2):84-95. doi: 10.1159/000509651. Epub 2020 Sep 29.
• Pearson N, Naylor PJ, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials. Pilot Feasibility Stud. 2020 Oct 31;6(1):167. doi: 10.1186/s40814-020-00634-w.
• Rizkalla MN, Henderson KK, Huntington-Alfano K, Heinking KP, Koronkiewicz A, Knees M, Hoffman H, Elahi F, Impens A. Does Osteopathic Manipulative Treatment Make a Neuropsychological Difference in Adults With Pain? A Rationale for a New Approach. J Am Osteopath Assoc. 2018 Sep 1;118(9):617-622. doi: 10.7556/jaoa.2018.136.
• Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev. 2011 Apr;12(4):282-94. doi: 10.1111/j.1467-789X.2010.00805.x. Epub 2010 Sep 29.
• Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014 Oct;25(10):1901-1914. doi: 10.1093/annonc/mdu042. Epub 2014 Apr 27.
• Majed B, Moreau T, Asselain B; Curie Institute Breast Cancer Group. Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points. Breast Cancer Res Treat. 2009 May;115(1):193-203. doi: 10.1007/s10549-008-0065-7. Epub 2008 Jun 12.
• Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H; Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial Group. Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial. Contemp Clin Trials. 2013 Mar;34(2):282-95. doi: 10.1016/j.cct.2012.12.003. Epub 2012 Dec 22.
• Li CI, Daling JR, Porter PL, Tang MT, Malone KE. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol. 2009 Nov 10;27(32):5312-8. doi: 10.1200/JCO.2009.23.1597. Epub 2009 Sep 8.
• Sauter ER, Scott S, Hewett J, Kliethermes B, Ruhlen RL, Basarakodu K, de la Torre R. Biomarkers associated with breast cancer are associated with obesity. Cancer Detect Prev. 2008;32(2):149-55. doi: 10.1016/j.cdp.2008.06.002. Epub 2008 Jul 17.
• Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010 Sep 10;28(26):4058-65. doi: 10.1200/JCO.2010.27.9935. Epub 2010 Aug 9.
• Buffa R, Mereu E, Comandini O, Ibanez ME, Marini E. Bioelectrical impedance vector analysis (BIVA) for the assessment of two-compartment body composition. Eur J Clin Nutr. 2014 Nov;68(11):1234-40. doi: 10.1038/ejcn.2014.170. Epub 2014 Aug 20.
• Vergnaud AC, Romaguera D, Peeters PH, van Gils CH, Chan DS, Romieu I, Freisling H, Ferrari P, Clavel-Chapelon F, Fagherazzi G, Dartois L, Li K, Tikk K, Bergmann MM, Boeing H, Tjonneland A, Olsen A, Overvad K, Dahm CC, Redondo ML, Agudo A, Sanchez MJ, Amiano P, Chirlaque MD, Ardanaz E, Khaw KT, Wareham NJ, Crowe F, Trichopoulou A, Orfanos P, Trichopoulos D, Masala G, Sieri S, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita HB, Ros MM, May A, Wirfalt E, Sonestedt E, Johansson I, Hallmans G, Lund E, Weiderpass E, Parr CL, Riboli E, Norat T. Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe: results from the European Prospective Investigation into Nutrition and Cancer cohort study1,4. Am J Clin Nutr. 2013 May;97(5):1107-20. doi: 10.3945/ajcn.112.049569. Epub 2013 Apr 3.
• Lachenbruch PA. A note on sample size computation for testing interactions. Stat Med. 1988 Apr;7(4):467-9. doi: 10.1002/sim.4780070403.
• FREEMAN GH, HALTON JH. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika. 1951 Jun;38(1-2):141-9. No abstract available.

Study record dates

Study Major Dates

• Study Start (Actual): December 19, 2023
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: December 1, 2023
• First Submitted That Met QC Criteria: December 1, 2023
• First Posted (Actual): December 11, 2023

Study Record Updates

• Last Update Posted (Actual): March 8, 2024
• Last Update Submitted That Met QC Criteria: March 7, 2024
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: quality of life; diet; hormonal therapy; treatment-related adverse events; osteopathic techniques
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: INT 107/23

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No